Samsung Biologics Earns Top ESG Risk Grade
Samsung Biologics has been recognized at the highest level for its non-financial risk management capabilities in the global market.Samsung Biologics announced on Nov. 4 that it obtained the top grade, "Negligible," in Sustainalytics' 2026 ESG Risk Rating. Sustainalytics, a subsidiary of Morningstar,
Samsung Biologics, a leading biopharmaceutical company, has received the highest possible grade for its environmental, social, and governance (ESG) risk management in the global market. This top-grade, "Negligible," was awarded by Sustainalytics, a division of Morningstar, in their 2026 ESG Risk Rating. Sustainalytics assesses the risks of approximately 16,000 companies worldwide annually, and their ratings often influence investment decisions by major institutional investors.
Samsung Biologics achieved a total ESG score of 9, which earned them the Negligible grade, a designation reserved for companies with a risk score below the critical threshold of 10. This marks a significant improvement, as the company moved up one level from its previous "Low Risk" rating from the previous year. Samsung Biologics secured the fourth position out of 842 companies within the global pharmaceutical industry group.
John Rim, the President and CEO of Samsung Biologics, attributed the positive outcome to the company's ongoing commitment to enhancing its comprehensive ESG risk management system. He emphasized that the company would continue to prioritize responsible management and transparent communication to further solidify trust among global stakeholders.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
